Silverback Therapeutics (NASDAQ:SBTX) Reaches New 1-Year High – What’s Next?

by · The Cerbat Gem

Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) hit a new 52-week high during trading on Thursday . The stock traded as high as $16.45 and last traded at $15.40, with a volume of 1005437 shares trading hands. The stock had previously closed at $16.05.

Silverback Therapeutics Price Performance

The firm has a 50-day moving average of $13.65 and a 200 day moving average of $10.87. The stock has a market capitalization of $555.29 million, a price-to-earnings ratio of -6.63 and a beta of 0.60.

Silverback Therapeutics Company Profile

(Get Free Report)

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

Featured Articles